Lurbinectedin is a chemotherapy drug that is used to treat small cell lung cancer (SCLC) [1]. According to the official website of the drug, Zepzelca, there is no information on the effects of lurbinectedin on breastfed infants or milk production. Therefore, it is not recommended to breastfeed while receiving treatment with lurbinectedin [2].

As for alternative treatments for breastfeeding mothers, there is no specific information on that matter. However, it is important to consult with a healthcare professional to discuss the risks and benefits of any alternative treatments. Clinical trials, such as the one conducted by the Dana-Farber Cancer Institute, may offer alternative treatments to patients who are not eligible for standard treatments or have not responded to them [3].

In conclusion, there is no information on alternative treatments for breastfeeding mothers who need to undergo treatment for small cell lung cancer. It is important to discuss any concerns with a healthcare professional and consider participating in clinical trials that may offer alternative treatments.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.zepzelca.com/
[3] https://www.dana-farber.org/clinical-trials2/detail/21-437/